News

Allergan, the Botox maker fending off a hostile bid by Valeant Pharmaceuticals and Pershing Square Capital Management, had had talks to acquire Salix Pharmaceuticals, another drug maker, according to people briefed on the matter.



If successful, Allergan’s acquisition of Salix would probably derail Valeant and Pershing Square’s $53 billion takeover attempt. It would also mean the end of Salix’s own deal to acquire Cosmo Technologies, the Irish unit of Cosmo Pharmaceuticals of Italy, in a tax inversion deal announced this summer.



But talks between Allergan and Salix continue and could still fall apart, these people said. One person briefed on the matter said the companies still had not come to terms.



And a deal would be a financial reach for Allergan. Salix has a market value of more than $10 billion, and its stock was up 16 percent in after-hours trading following a report in The Wall Street Journal about talks between the companies.



SHARE

SAVE

0 COMMENTS

Show Full Article

Most Popular on NYTimes.com



Airstrikes by U.S. and Allies Hit ISIS Targets in Syria



Rockefellers, Heirs to an Oil Fortune, Will Divest Charity of Fossil Fuels



OP-ED COLUMNIST

Those Lazy Jobless



PAYING TILL IT HURTS

After Surgery, Surprise $117,000 Medical Bill From Doctor He Didn’t Know



U.S. Ramping Up Major Renewal in Nuclear Arms



OP-ED CONTRIBUTOR

Why Poor Students Struggle



White House Intruder’s Past Raises Concern



Weeks of U.S. Strikes Fail to Dislodge ISIS in Iraq

Back to top

Home

World

U.S.

Politics

The Upshot

N.Y. / Region

Business Day

Technology

Sports

Opinion

Science

Health

Arts

Style

Photos

Video

Most Emailed

More

© 2014 The New York Times Company

News